Enhanced effect of triazolam with diltiazem

British Journal of Clinical Pharmacology

Volumn 43, Issue 4, 1997, Pages 367-372

  Kosuge, Kazuhiro ^a   Nishimoto, Masahiko ^a   Kimura, Masahiko ^a   Umemura, Kazuo ^a   Nakashima, Mitsuyoshi ^a   Ohashi, Kyoichi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diltiazem; Drug interaction; Pharmacokinetics; Triazolam

Indexed keywords

DILTIAZEM; PLACEBO; TRIAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ELECTROENCEPHALOGRAM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 0030895835     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00580.x     Document Type: Article

References (17)

1. Schlantz K, Myre S, Bottorff M. Pharmacokinetic interactions with calcium channel antagonists (Part 1). Clin Pharmacokin 1991; 21: 344-356.
2. Tateishi T, Ohashi K, Sudo T, et al. Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. J Clin Pharmacol 1989; 29: 994-997.
3. Ohashi K, Sudo T, Sakamoto K, et al. The influence of pretreatment periods with diltiazem on nifedipine kinetics. J Clin Pharmacol 1993; 33: 222-225.
4. Kronbach T, Mathys D, Umeno M, Gonzales F, Meyer U. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36: 89-96.
5. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56: 601-607.
6. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55: 481-485.
7. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994; 37: 221-225.
8. Varhe, A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism, Clin Pharmacol Ther 1996; 59: 369-375.
9. Cairns ER, Dent BR, Ouwerkerk JC, Porter LJ. Quantitative analysis of alprazolam and triazolam in hemolysed whole blood and liver digest by GC/MS/NICI with deuterated internal standards. J Anal Toxicol 1994; 18: 1-6.
10. Van S, AL, Kroon J, Schoemaker H, Pieters P, Breimer D, Cohen A. A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analogue lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther 1991; 50: 172-180.
11. Allonen H, Ziegler G, Klots U. Midazolam kinetics, Clin Pharmacol Ther 1981; 30: 653-661.
12. Robin DW, Lee M, Hasan SS, Wood AJ. Triazolam in cirrhosis: pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993; 54: 630-637.
13. Ohashi K, Tateishi T, Sudo T, et al. Effects of diltiazem on the pharmcokinetics of nifedipine. J Cardiovasc Pharmacol 1990; 15: 96-101.
14. Kinirons MT, Lang CC, He HB, Ghebreselasie K, Shay S, Robin DW, Wood AJJ. Triazolam pharmacokinetics and pharmacodynamics in Caucasians and southern Asians: ethnicity and CYP3A activity. Br J Clin Pharmacol 1996; 41: 69-72.
15. Ahsan CH, Renwick AG, Waller DG, Challenor VF, George CF, Amanullah M. The influences of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54: 329-338.
16. Van SA, Mandema JW, Tuk B, et al. A comparison of the concentration-effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity. Br J Clin Pharmacol 1993; 36: 109-115.
17. Mandema JW, Danhof M. Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet 1992; 23: 191-215.